Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.49 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | PLAT | P00750 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PPIB | P23284 | 1/20 | 0.42 |
| ▸ | PPIA | P62937 | 1/20 | 0.42 |
| ▸ | PPID | Q08752 | 1/20 | 0.42 |
| ▸ | PPIG | Q13427 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452919 | 0.85 | MEN1 (0.55) | TOP2ATOP2BALDH1A1LMNANPC1 | |
| SCHEMBL12898184 | 0.83 | NAAA (0.54) | TOP2ATOP2BALDH1A1NPC1RAB9A | |
| SCHEMBL1936309 | 0.83 | TOP2A (0.50) | TOP2ATOP2BALDH1A1TPSAB1PRSS1 | |
| SCHEMBL18232048 | 0.83 | NAAA (0.54) | TOP2ATOP2BALDH1A1NPC1RAB9A | |
| SCHEMBL25884564 | 0.82 | TOP2A (0.47) | TOP2ATOP2BALDH1A1TPSAB1PRSS1 | |
| SCHEMBL22198338 | 0.82 | TPSAB1 (0.48) | F2PLAUPLATALDH1A1TPSAB1 | |
| SCHEMBL15650646 | 0.82 | NPC1 (0.51) | ALDH1A1PPIBPPIAPPIDPPIG | |
| SCHEMBL23275293 | 0.81 | TOP2A (0.49) | TOP2ATOP2BALDH1A1CYP3A4NPC1 | |
| SCHEMBL12291924 | 0.81 | TOP2A (0.49) | TOP2ATOP2BALDH1A1TPSAB1PRSS1 | |
| SCHEMBL20497336 | 0.81 | KMT2A (0.51) | TOP2ATOP2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637833-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | Genentech, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| WO-2024138128-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | GENENTECH, INC. (US) | 2024-06-27 | — | — | WO | claimed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230272100-A1 | ANTIBODIES AGAINST OX-40 AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-31 | — | — | US | disclosed |
| US-11661621-B2 | Self-immolative probes for enzyme activity detection | ENZO LIFE SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | GENENTECH, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210101906-A2 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-04-08 | — | — | US | disclosed |
| WO-2021045632-A1 | CANCER VACCINE | VICTORIA LINK LTD (NZ) | 2021-03-11 | — | — | WO | disclosed |
| WO-2020231274-A1 | GLYCOPEPTIDE VACCINE | VICTORIA LINK LTD (NZ) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020060944-A1 | COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-20180092981-A9 | MATERIALS AND METHODS RELATING TO LINKERS FOR USE IN PROTEIN DRUG CONJUGATES | GLYTHERA LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
| US-20170306035-A1 | ANTIBODIES AGAINST OX40 AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-10-26 | — | — | US | disclosed |
| US-20170232108-A1 | MATERIALS AND METHODS RELATING TO LINKERS FOR USE IN PROTEIN DRUG CONJUGATES | GLYTHERA LIMITED (GB) | 2017-08-17 | — | — | US | disclosed |
| US-9644032-B2 | Antibodies against OX40 and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160347849-A1 | ANTIBODIES AGAINST OX40 AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-12-01 | — | — | US | disclosed |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | POU5F1, POU2F1, POU2F2 | TOP2A 2593/4885TOP2B 1597/4885F2 4881/4885 |
| US-20170232108-A1 | MATERIALS AND METHODS RELATING TO LINKERS FOR USE IN PROTEIN DRUG CONJUGATES | ILK, FCGRT, SDCBP | TOP2A 1152/4885TOP2B 1664/4885F2 3148/4885 |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | TOP2A 1150/4885TOP2B 2171/4885F2 2725/4885 |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AR, PSMA1, NR2E3 | TOP2A 3833/4885TOP2B 4010/4885F2 4823/4885 |
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | ADRM1, SSB, FCER2 | TOP2A 1553/4885TOP2B 2191/4885F2 4179/4885 |
| US-11661621-B2 | Self-immolative probes for enzyme activity detection | MGAM, SI, ENGASE | TOP2A 3824/4885TOP2B 4183/4885F2 3490/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | TOP2A 2615/4885TOP2B 2873/4885F2 4831/4885 |
| US-20230272100-A1 | ANTIBODIES AGAINST OX-40 AND USES THEREOF | IGLV6-57, CD47, IGSF11 | TOP2A 2751/4885TOP2B 3357/4885F2 4752/4885 |
| US-20160347849-A1 | ANTIBODIES AGAINST OX40 AND USES THEREOF | IGSF11, IGLV6-57, CD40LG | TOP2A 2767/4885TOP2B 3305/4885F2 4856/4885 |
| US-20210101906-A2 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | TOP2A 1965/4885TOP2B 1315/4885F2 3820/4885 |
| US-20170306035-A1 | ANTIBODIES AGAINST OX40 AND USES THEREOF | IGSF11, IGLV6-57, CD40LG | TOP2A 2767/4885TOP2B 3305/4885F2 4856/4885 |
| US-20180092981-A9 | MATERIALS AND METHODS RELATING TO LINKERS FOR USE IN PROTEIN DRUG CONJUGATES | ILK, FCGRT, SDCBP | TOP2A 1152/4885TOP2B 1664/4885F2 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.